Market

    Will lenacapavir be added to US CDC HIV prevention guidelines by end of 2025?

    2
    Resolution / Starting Odds

    Yes • 50%

    No • 50%

    Updates from the US Centers for Disease Control and Prevention (CDC)

    Story

    Lenacapavir Named Science's Breakthrough of 2024 for HIV Prevention

    Lenacapavir Named Science's Breakthrough of 2024 for HIV Prevention

    Dec 15, 2024, 03:44 PM

    The injectable HIV drug lenacapavir has been recognized by the journal 'Science' as the Breakthrough of the Year for 2024. Developed by Gilead Sciences, lenacapavir targets the HIV capsid, a protein shell that protects the virus's genetic material, preventing the virus from replicating within human cells. This drug, administered as a subcutaneous injection every six months, has shown remarkable efficacy in preventing HIV infection, with trials reporting a 100% success rate in African adolescent girls and young women, and a 99.9% effectiveness in gender-diverse individuals. Lenacapavir's unique mechanism of action, as a capsid inhibitor, sets it apart from traditional antiretroviral drugs, offering hope for significantly reducing global HIV infection rates when used as pre-exposure prophylaxis (PrEP).

    View original story

    Browse all stories on DeepNewz

    Visit